Lana Gettman Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Biography and Research Information
OverviewAI-generated summary
Lana Gettman's research focuses on the evaluation and description of new pharmaceutical agents. Her recent publications include reviews of lecanemab-irmb for Alzheimer's disease, tirzepatide for type 2 diabetes, and novel treatments for SARS-CoV-2. She has also published on finerenone, difelikefalin, and avacopan, as well as faricimab-svoa for macular degeneration and diabetic macular edema, and omidenepag isopropyl for glaucoma.
Gettman's work also extends to educational practices within pharmacy programs, with publications on assessing skills in interpreting culture and sensitivity reports and implementing proactive support models for student success. Her scholarship metrics include an h-index of 5 with 62 total citations across 12 publications. She has collaborated with Kristin Kellett on one shared publication.
Metrics
- h-index: 5
- Publications: 13
- Citations: 63
Selected Publications
-
Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease (2024)
-
New Drugs: Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension (2023)
-
New Drug: Tirzepatide (Mounjaro<sup>™</sup>) (2023)
-
New Drugs Update: Three Novel Treatments for SARS-CoV-2 (2022)
-
New Drugs Update: Finerenone, Difelikefalin, and Avacopan (2022)
-
New Drugs (2021)
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics